New marburg vaccine trial launches: could it stop the deadly virus?
NCT ID NCT07425821
First seen Feb 28, 2026 · Last updated May 12, 2026 · Updated 7 times
Summary
This early-stage trial tests a new vaccine designed to protect against Marburg virus disease, a rare but severe illness. About 112 healthy adults aged 18 to 50 will receive either the vaccine or a placebo to check for side effects and measure immune responses. The goal is to see if the vaccine is safe and prompts the body to produce antibodies against the virus.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARBURG VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
George Washington University
RECRUITINGWashington D.C., District of Columbia, 20052, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johnson County Clin-Trials
RECRUITINGLenexa, Kansas, 66219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.